Literature DB >> 32002848

Fixed Drug Eruptions: An Update, Emphasizing the Potentially Lethal Generalized Bullous Fixed Drug Eruption.

Shreya Patel1, Ann M John2, Marc Zachary Handler1, Robert A Schwartz3.   

Abstract

A fixed drug eruption (FDE) is a relatively common reaction associated with more than 100 medications. It is defined as a same-site recurrence with exposure to a particular medication. The primary approach and treatment for all types of FDEs are to identify and remove the causative agent, often accomplished by a thorough history of medication and other chemical exposures, and possibly prior episodes. The most common category of FDE, localized FDE, whether bullous or non-bullous, is self-limited. Although one can confirm the causative agent using oral challenge testing, it is not recommended due to the risk of severe exacerbation or possible generalization; patch testing is now preferred. Bullous FDE may resemble erythema multiforme. Treatment of localized FDE includes medication removal, patient counseling, and symptomatic relief. Failure to remove the causative agent in localized FDE can lead to recurrence, which is associated with increased inflammation, hyperpigmentation, and risk of a potentially lethal generalized bullous FDE (GBFDE), which may resemble Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Distinguishing GBFDE from SJS and TEN is salient and will be stressed: GBFDE has more rapid onset in 1-24 h rather than in weeks, less or no mucosal involvement, less or no systemic involvement, and a tendency for a more favorable prognosis; however, recent experience suggests it may be just as life-threatening. This review will provide a comprehensive update and approach to diagnosis and management.

Entities:  

Year:  2020        PMID: 32002848     DOI: 10.1007/s40257-020-00505-3

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  7 in total

1.  Generalized bullous fixed drug eruption after Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccination.

Authors:  K Wantavornprasert; N Noppakun; J Klaewsongkram; P Rerknimitr
Journal:  Clin Exp Dermatol       Date:  2021-10-10       Impact factor: 4.481

2.  A case of recurrent fixed drug eruption following two different coronavirus disease 2019 vaccination verified through intradermal and patch tests.

Authors:  Jung Eun Seol; Sang Woo Ahn; Seung Hee Jang; Seong Min Hong; Mi Yeong Kim; Hyojin Kim
Journal:  JAAD Case Rep       Date:  2022-08-27

3.  Fixed drug eruption.

Authors:  Yu-Ju Chou; Hua-Ching Chang
Journal:  CMAJ       Date:  2022-08-02       Impact factor: 16.859

4.  Ecstasy-induced fixed drug eruption.

Authors:  Ophélie Barbier; Alia Galadari; Brigitte Milpied; Paola Sanchez; Stéphanie Kassab; Ruben Goncalves; Anne-Sophie Darrigade
Journal:  Contact Dermatitis       Date:  2022-04-29       Impact factor: 6.419

5.  Hypopigmented penile fixed drug eruption.

Authors:  Perpetua U Ibekwe; Hafees O Ajibola; Zainabb Babba; Grace Otokpa; Raphael Solomon; Bob A Ukonu
Journal:  Clin Case Rep       Date:  2022-09-24

6.  Nicotine-induced bullous fixed drug eruption.

Authors:  Brynn Sargent; Lina Saeed; Dani Zhao; Anna-Marie Hosking; Hadas Skupsky; Maryam Safaee
Journal:  JAAD Case Rep       Date:  2022-08-27

Review 7.  Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine.

Authors:  Robert A Schwartz; Camila K Janniger
Journal:  Dermatol Ther       Date:  2020-04-16       Impact factor: 3.858

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.